PURPOSE: Tumor risk stratification during diagnosis is paramount for children with medulloblastomas, primarily because very young patients (<3 years) suffer cognitive deficits from radio- and chemotherapy sequelae. Thus, distinguishing tumors that are biologically more aggressive is essential for medulloblastoma management to maximize the delay in radiation treatment without adversely affecting survival outcome. In this context, current strategies for risk assessment, which are based on clinical parameters, remain unsatisfactory. EXPERIMENTAL DESIGN: Array-based comparative genomic hybridization (aCGH) was used to identify chromosomal copy number abnormalities in a cohort of 49 medulloblastoma tumors. Based on the karyotypes generated from aCGH analysis, each tumor was scored for copy number abnormalities, and the log-rank test was used to evaluate whether any cytogenetic events were associated with survival. RESULTS: A single copy gain of 1q was shown to be a negative prognostic marker for survival in medulloblastomas with high statistical significance (P < 0.0001, log-rank test). CONCLUSION: A gain of 1q provides a potential means of predicting overall survival in medulloblastoma.
PURPOSE:Tumor risk stratification during diagnosis is paramount for children with medulloblastomas, primarily because very young patients (<3 years) suffer cognitive deficits from radio- and chemotherapy sequelae. Thus, distinguishing tumors that are biologically more aggressive is essential for medulloblastoma management to maximize the delay in radiation treatment without adversely affecting survival outcome. In this context, current strategies for risk assessment, which are based on clinical parameters, remain unsatisfactory. EXPERIMENTAL DESIGN: Array-based comparative genomic hybridization (aCGH) was used to identify chromosomal copy number abnormalities in a cohort of 49 medulloblastoma tumors. Based on the karyotypes generated from aCGH analysis, each tumor was scored for copy number abnormalities, and the log-rank test was used to evaluate whether any cytogenetic events were associated with survival. RESULTS: A single copy gain of 1q was shown to be a negative prognostic marker for survival in medulloblastomas with high statistical significance (P < 0.0001, log-rank test). CONCLUSION: A gain of 1q provides a potential means of predicting overall survival in medulloblastoma.
Authors: Laura Giunti; Marilena Pantaleo; Iacopo Sardi; Aldesia Provenzano; Alberto Magi; Stefania Cardellicchio; Francesca Castiglione; Lorenzo Tattini; Francesca Novara; Anna Maria Buccoliero; Maurizio de Martino; Lorenzo Genitori; Orsetta Zuffardi; Sabrina Giglio Journal: Am J Cancer Res Date: 2014-05-26 Impact factor: 6.166
Authors: Eric J Gratias; Jeffrey S Dome; Lawrence J Jennings; Yueh-Yun Chi; Jing Tian; James Anderson; Paul Grundy; Elizabeth A Mullen; James I Geller; Conrad V Fernandez; Elizabeth J Perlman Journal: J Clin Oncol Date: 2016-07-11 Impact factor: 44.544
Authors: Helena Nord; Susan Pfeifer; Pelle Nilsson; Johanna Sandgren; Svetlana Popova; Bo Strömberg; Irina Alafuzoff; Monica Nistér; Teresita Díaz de Ståhl Journal: J Neurooncol Date: 2011-10-07 Impact factor: 4.130
Authors: Darlene Gabeau-Lacet; David Engler; Sumeet Gupta; George A Scangas; Rebecca A Betensky; Fred G Barker; Jay S Loeffler; David N Louis; Gayatry Mohapatra Journal: J Neuropathol Exp Neurol Date: 2009-10 Impact factor: 3.685